AstraZeneca boss Pascal Soriot dismisses exit talk
AstraZeneca PLC (LSE:AZN) boss Pascal Soriot has told Bloomberg that reports of his imminent departure from the drugmaker are “fake news.” Soriot, speaking at the European Society for Medical Oncol...
AstraZeneca gains European approval for lung cancer drug
AstraZeneca PLC (LSE:AZN) has announced that its jointly developed lung cancer drug has been approved for use in the European Union. Enhertu, which has been co-developed with Daiichi Sankyo, receiv...
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know
The latest trading day saw Astrazeneca (AZN) settling at $64.42, representing a -1.26% change from its previous close.
AstraZeneca shares fall as abstract for lung cancer trial data disappoints
Shares in AstraZeneca fell more than 4% on Wednesday after the publication of an abstract on its experimental precision drug's use in lung cancer in a late-stage trial disappointed some analysts.
AstraZeneca leads FTSE fallers with no obvious reason
AstraZeneca PLC (LSE:AZN) shares were the biggest faller on the FTSE 100 on Wednesday, down 3.6%, with no obvious reason for the sell-off. News and broker comments on the Anglo-Swedish drug giant ...
AstraZeneca's (AZN) Tagrisso Combo Gets FDA's Priority Review
The FDA accepts and grants priority review to AstraZeneca's (AZN) sNDA, seeking approval of Tagrisso combined with chemotherapy as a first-line treatment for EGFR-mutated advanced NSCLC. A decision...
AstraZeneca's Tagrisso-chemo combo given priority review in US
The combination of AstraZeneca's cancer drug, Tagrisso, with chemotherapy has been been accepted and granted priority review by the U.S. Food and Drug Administration (FDA), the British drugmaker sa...
Why the Market Dipped But (AZN) Gained Today
Astrazeneca (AZN) concluded the recent trading session at $68.11, signifying a +0.15% move from its prior day's close.
Here's Why Astrazeneca (AZN) Gained But Lagged the Market Today
Astrazeneca (AZN) concluded the recent trading session at $67.42, signifying a +0.81% move from its prior day's close.
2 Nasdaq 100 Stocks That Are Surefire Buys in October, and 1 to Avoid Like the Plague
The Nasdaq 100 has been absolutely whipsawed in recent years. Two Nasdaq 100 stocks possess the necessary catalysts to fuel double-digit earnings growth.
AstraZeneca (AZN) Settles Heartburn Drugs Lawsuits for $425M
AstraZeneca (AZN) agrees to pay $425 million to settle lawsuits related to heartburn drugs, Nexium and Prilosec.
AstraZeneca Settles Lawsuits Alleging Heartburn Drugs Caused Kidney Disease For $425 Million
The payout will settle the claims of 11,000 people who said they weren't property warned Nexium and Prilosec could cause chronic kidney disease.
AstraZeneca settles Nexium heartburn drug cases for US$425m
AstraZeneca said it has settled a suite of US legal claims over heartburn treatments Nexium and Prilosec for US$425 million. The UK pharma said the agreements effectively resolve the product liabil...
AstraZeneca to pay $425 mln to settle Nexium, Prilosec litigation in US
British drugmaker AstraZeneca on Tuesday said it will pay $425 million to settle product liability litigations related to acid-reflux medicine Nexium and heartburn drug Prilosec in the United States.
Related Companies